Protagonist Therapeutics Inc.

04/27/2021 | Press release | Archived content

Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting